Biotech News
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
ir.rocketpharma.com2026-05-07 20:13 EST
Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher